Cancer Therapeutics Maker, Boundless Bio, Drops 11% after $100M IPO

Shares of Boundless Bio Inc., a cancer therapeutics maker backed by Bayer AG, fell nearly 11% after raising $100 million in a US initial public offering. The San Diego-based company’s shares declined to $14.25 each on Thursday, below their IPO price of $16 — the midpoint of a $15 to $17 marketed range.